Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual) € in Millions			1 Months Ended	3 Months Ended
	May 10, 2022 USD ($)	Jun. 24, 2020	Jan. 31, 2023 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 16, 2021 USD ($)	Dec. 16, 2021 EUR (€)	Jul. 08, 2021 shares	Dec. 01, 2020
Revenue from Contract with Customer, Excluding Assessed Tax				$ 978,052	$ 648,427
Upfront Payment Payable							$ 500,000
Deferred License Revenue, Current				176,471		$ 176,471
Deferred License Revenue, Net of Current Portion				132,353		$ 176,471
Cost of Goods and Services Sold, Total				726,918	404,746
Gain (Loss) on Sale of Investments				989,319	(0)
Alphazyme [Member]
Sale of Stock, Percentage of Ownership after Transaction		2.50%
Proceeds from Sale, Maturity and Collection of Investments			$ 1,270,000	1,270,000
Gain (Loss) on Sale of Investments				989,000
ID Biologics Inc [Member]
Investment Owned, Balance, Shares (in shares) | shares									129,661
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners									0.37%
Cost of Goods and Services Sold, Total				0	109,000
Alphazyme [Member]
Ownership Percentage										1.99%
Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				933,934	533,721
A Global Food Ingredient Company [Member]
Collaborative Arrangement, Payment for Research and Development Agreement	$ 4,100,000
Collaborative Arrangement, Duration Of Agreement (Year)	2 years
A Global Food Ingredient Company [Member] | Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				339,000
A Global Food Ingredient Company [Member] | Success Fees [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				65,500
Janssen Pharmaceutical Companies [Member]
Deferred License Revenue, Current				176,000
Deferred License Revenue, Net of Current Portion				132,000
Deferred License Revenue				44,000	15,000
Janssen Pharmaceutical Companies [Member] | Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				$ 189,000	$ 15,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total | €								€ 1.6